At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 22 target
Drug / intervention
ICP-189drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ia /Ib Dose Finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating ICP-189 for Patients With Advanced Solid Tumors. Targeting 22 participants across 1 site.
Detailed Summary
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients With Advanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
2023202420252026
First PostedMay 2022
Enrollment StartMay 2022
Primary CompletionMay 2024
Study CompletionJan 2026
TodayJul 2026
First PostedMay 11, 2022
Enrollment StartMay 31, 2022
Primary CompletionMay 31, 2024
Study CompletionJan 31, 2026
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 4.1 years ago
Interventions
ICP-189drug
Administered orally